Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 10/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444560 | 0.92 | AKR1C3 (0.56) | AKR1C3AKR1C1AGTR2NOTUMHTR2A | |
| SCHEMBL5007409 | 0.91 | AKR1C3 (0.51) | AKR1C3AKR1C1AGTR2NOTUMHTR2A | |
| SCHEMBL5004714 | 0.80 | NOTUM (0.51) | NOTUMHTR2AHTR2CHRH1HTR2B | |
| SCHEMBL5009505 | 0.80 | ALDH1A1 (0.48) | AGTR2HTR2AHTR2CHRH1HTR2B | |
| SCHEMBL6373468 | 0.79 | CYP2D6 (0.59) | AKR1C3AKR1C1AGTR2HTR2AHTR2C | |
| SCHEMBL5004640 | 0.79 | ALDH1A1 (0.50) | AGTR2HTR2AHTR2CHRH1HTR2B | |
| SCHEMBL5009507 | 0.78 | AKR1C3 (0.54) | AKR1C3AKR1C1AGTR2NOTUMSLC18A3 | |
| SCHEMBL11665023 | 0.75 | AKR1C3 (0.74) | AKR1C3AKR1C1HTR2CGRIN2BNPC1 | |
| SCHEMBL7388336 | 0.75 | AKR1C3 (0.74) | AKR1C3AKR1C1HTR2CGRIN2BNPC1 | |
| SCHEMBL717453 | 0.75 | AKR1C3 (0.74) | AKR1C3AKR1C1HTR2CGRIN2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | AKR1C3 1826/4885AKR1C1 2592/4885AGTR2 2698/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | AKR1C3 1826/4885AKR1C1 2592/4885AGTR2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.